<DOC>
	<DOC>NCT00735449</DOC>
	<brief_summary>Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Be at least 18 years of age Give written informed consent Be in good general health as determined by your doctor Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension If you are a female of child bearing potential, you must be willing to practice effective contraception for the duration of the study (i.e., abstinence, spermicide, condoms, or birth control pills) Understand the study instructions, and be able to follow the study instructions; and Be likely to complete the entire study period (12 weeks), including all regularly scheduled study visits Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation History of severe renal or hepatic impairment Subjects with severe cardiovascular disease should not be enrolled unless their disease is controlled and clearance has been obtained from the subject's primary care physician and/or cardiologist Contraindications to betaadrenoceptor antagonist therapy such as chronic obstructive pulmonary disease, bronchial asthma, sinus bradycardia, second and third degree atrioventricular block, overt cardiac failure and cardiogenic shock or uncontrolled congestive heart failure Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>